April 10 OncoMed Pharmaceuticals Inc
said on Monday its experimental drug, in combination with
Celgene Corp's Abraxane and chemotherapy, failed a
mid-stage study as an initial therapy for advanced pancreatic
The trial was testing OncoMed's demcizumab, Abraxane and
chemotherapy versus a combination of Abraxane, chemotherapy and
The main goal was to slow disease progression.
Based on the lack of benefit over standard-of-care, which
performed remarkably well, the company will discontinue the
trial, OncoMed CEO Paul Hastings said.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by